期刊文献+

泛耐药鲍曼不动杆菌的体外联合药敏分析 被引量:9

Combined drug sensitivity test of 50 strains of extensively drug- resistant Acinetobacter baumannii
暂未订购
导出
摘要 目的评价美罗培南与多西环素、环丙沙星、舒巴坦及头孢哌酮/舒巴坦联合用药对泛耐药鲍曼不动杆菌的体外抗菌效应。方法采用棋盘法设计,微量肉汤稀释法测定不同浓度组合的抗菌药物对50株临床分离的泛耐药鲍曼不动杆菌的最低抑菌浓度,并计算部分抑菌浓度(FIC)指数判定联合效应。结果美罗培南与多西环素联用后,其MIC50显著下降,FIC指数分布:FIC≤0.5占38%,0.5<FIC≤1占62%,1<FIC≤2为0,FIC>2为0。美罗培南与环丙沙星联用后,其MIC50下降不明显,FIC指数分布:FIC≤0.5为0,0.5<FIC≤1占56%,1<FIC≤2为44%,FIC>2为0。美罗培南与舒巴坦联用后,其MIC50明显下降,FIC指数分布:FIC≤0.5为26%,0.5<FIC≤1占74%,1<FIC≤2为0,FIC>2为0。美罗培南与头孢哌酮/舒巴坦联用后,其MIC50有所下降,FIC指数分布:FIC≤0.5为10%,0.5<FIC≤1占90%,1<FIC≤2为0,FIC>2为0。结论美罗培南与多西环素、舒巴坦或者头孢哌酮/舒巴坦联合,对泛耐药鲍曼不动杆菌均表现为协同和相加作用,没有无关作用和拮抗作用,具有良好的体外抗菌活性;而美罗培南与环丙沙星联合表现出的相加作用和无关作用比例相当,对泛耐药鲍曼不动杆菌的体外抗菌活性较差。 Objective To study the in vitro antibacterial activity of meropenem combined with doxycycline, ciprofloxacin, sulbactam or cefoperazone/sulbactam against clinically isolated extensively drug-resistant Acinetobacter baumannii (XDRAB). Methods Using a checker board synergy design, the minimal inhibitory concentration (MIC) of antibiotics against 50 isolates of XDRAB was determined by broth microdilution antifungal susceptibility test. The fractional inhibitory concentration (FIC) index was calculated to determine the combined effect of the antibiotics. Results Meropenem showed significantly reduced MIC50 and enhanced antimicrobial activities when combined with doxycycline, sulbactam or cefoperazone/sulbactam. The FIC results suggested that the main actions of doxycycline, sulbactam, and cefoperazone/sulbactam were synergistic (38%, 26%, and 10%, respectively) and addictive (62%, 74%, and 90%, respectively) without indifferent or antagonistic effects. The main actions of meropenem combined with ciprofloxacin were additive (56%) and indifference (44%) with synergistic and antagonistic effects. Conclusion Meropenem combined with doxycycline, sulbactam or cefoperazone/sulbactam shows excellent activity against clinical isolates of XDRAB.
出处 《南方医科大学学报》 CAS CSCD 北大核心 2014年第11期1697-1701,共5页 Journal of Southern Medical University
基金 "南方地区泛耐药细菌分子分型及耐药基因多态性研究"专项基金(2010C001)
关键词 泛耐药鲍曼不动杆菌 美罗培南 联合用药 药物敏感性 部分抑菌浓度指数 extensively drug-resistant Acinetobater baumannii meropenem antibiotics combination drug sensitivity fractional inhibitoryconcentration index
  • 相关文献

参考文献11

  • 1李耘,吕媛.Mohnarin 2009年度报告:非发酵革兰阴性杆菌耐药监测[J].中国临床药理学杂志,2011,27(5):348-351. 被引量:37
  • 2胡付品,朱德妹,汪复,蒋晓飞,杨青,徐英春,张小江,孙自镛,陈中举,王传清,王爱敏,倪语星,孙景勇,俞云松,林洁,单斌,杜艳,徐元宏,沈继录,张泓,孔菁,卓超,苏丹虹,张朝霞,季萍,胡云建,艾效曼,黄文祥,贾蓓,魏莲花,吴玲.2011年中国CHINET细菌耐药性监测[J].中国感染与化疗杂志,2012,12(5):321-329. 被引量:529
  • 3陈佰义,何礼贤,胡必杰,倪语星,邱海波,石岩,施毅,王辉,王明贵,杨毅,张菁,俞云松.中国鲍曼不动杆菌感染诊治与防控专家共识[J].中国医药科学,2012,2(8):3-8. 被引量:537
  • 4徐雅萍,龚美亮,夏静静,周玉,方向群,李晓霞,白洁.美罗培南与米诺环素及头孢哌酮/舒巴坦对耐碳青霉烯类鲍氏不动杆菌的联合药敏研究[J].中华医院感染学杂志,2012,22(6):1251-1253. 被引量:11
  • 5Higgins PG, Wisplinghoff H, Stefanik D, et al. In vitro activities of the beta-lactamase inhibitors clavulanic acid, sulbactam, and tazobactam alone or in combination with beta-lactams against epidemiologically characterized multidrug-resistant Acinetobacter baumannii strains [J]. Antimicrob Agents Chemother, 2004, 48(5): 1586-92.
  • 6Levin AS. Multiresistant acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem[J]. Clin Microbiol Infect, 2002, 8(3): 144-53.
  • 7Levin AS, Levy CE, Manrique AE, et al. Severe nosocomial infections with imipenem-resistant Acinetobacter baumarmii treated with ampicillin/sulbactam [J]. Int J Antimicrob Agents, 2003, 21 (1): 58-62.
  • 8李娅娟,刘蓬蓬,李萍,孙伟伟,郝晓佳.头孢哌酮/舒巴坦对革兰阴性菌的抗菌活性[J].中华医院感染学杂志,2006,16(5):554-556. 被引量:40
  • 9Ko WC, Lee HC, Chiang SR, et al. In vitro and in vivo activity of meropenem and sulbactam against a multidrug-resistant Aeinetobacter baumannii strain[J]. J Antimicrob Chemother, 2004, 53(2): 393-5.
  • 10Kiffer CR, Sampaio JL, Sinto S, et al. In vitro synergy test of meropenem and sulbactam against clinical isolates of Acinetobacter baumannii[J]. Diagn Microbiol Infect Dis, 2005, 52(4): 317-22.

二级参考文献77

  • 1李家泰,李耘,齐慧敏,代表中国细菌耐药监测研究组.2002—2003年中国革兰阴性细菌耐药性监测研究[J].中华检验医学杂志,2005,28(1):19-29. 被引量:296
  • 2张小江,徐英春,俞云松,杨青,汪复,朱德妹,倪语星,孙景勇,孙自镛,简翠,胡云建,艾效曼,张泓,李万华,贾蓓,黄文祥,王传清,王爱敏,魏莲花,吴玲,卓超,苏丹虹,张朝霞,季萍,徐元宏,熊自忠,沈继录,单斌,杜艳.2009年中国CHINET鲍曼不动杆菌细菌耐药性监测[J].中国感染与化疗杂志,2010,10(6):441-446. 被引量:138
  • 3李燕,宋瑱,宋晓红.耐环丙沙星鲍氏不动杆菌的gyrA基因及parC基因突变分析[J].中华医院感染学杂志,2006,16(1):6-8. 被引量:13
  • 4李娅娟,刘蓬蓬,李萍,孙伟伟,郝晓佳.头孢哌酮/舒巴坦对革兰阴性菌的抗菌活性[J].中华医院感染学杂志,2006,16(5):554-556. 被引量:40
  • 5李松.152株鲍曼不动杆菌耐药性分析[J].中国感染控制杂志,2007,6(3):194-196. 被引量:17
  • 6McGowan JE. Resistance in nonfermenting gram - negative bacteria: multidrug resistance to the maximum [ J ]. Associat Profess Infect Control Epidemiol, 2006; 34( Suppl. 1 ) : S29 -S37.
  • 7Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing; nineteenth informational supplement. Wayne: Clinical and Laboratory Standards Institute, 2009.
  • 8Turmer PJ. MYSTIC Europe 2007 : activity of meropenem and other broad - spectrum agents against nosocomial isolates [ J ]. Diag Microb Infect Dis ,2009 ; 63 : 217 - 222.
  • 9Bouchillon SK, Iredell JR, Barkham T, et al. Comparative in vitro activity of tigecycline and other antimicrobials against Gram - negative and Gram - positive organisms collected from the Asia - Pacific Rim as part of the Tigecycline Evaluation and Surveillance Trial (TEST) [J]. Int JAntimicrob Agents, 2009; 33:130 -136.
  • 10Yau W, Owen RJ, Poudyal A, et al. Colistin hetero - resistance in muhidrug - resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme [ J ]. J Infect,2009 ;58 : 138 - 144.

共引文献1120

同被引文献88

引证文献9

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部